Clinical Trials
71 trialsNCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00661622 2025-05-16
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Thomas Jefferson University
Phase 2 Completed
NCT02465268 2025-01-14
ATTAC-II
University of Florida
Phase 2 Completed
NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT04013672 2024-08-28
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02728102 2024-05-07
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT02169609 2024-04-22
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Phase 2 Completed
NCT02297698 2023-12-12
HER3+
Cancer Insight, LLC
Phase 2 Completed
NCT02636582 2023-12-05
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00071981 2023-06-28
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03113851 2023-06-13
Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT00005780 2023-01-31
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02593123 2023-01-23
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Phase 2 Completed
NCT01700673 2022-10-18
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02873819 2022-03-08
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
Phase 2 Completed
NCT02703714 2022-01-25
Pembrolizumab and GM-CSF in Biliary Cancer
University of California, San Francisco
Phase 2 Completed
NCT00488592 2021-07-12
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02677155 2021-03-01
Lymvac-2
Oslo University Hospital
Phase 2 Completed
NCT01341652 2021-01-20
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT01570036 2020-12-02
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Cancer Insight, LLC
Phase 2 Completed
NCT00562328 2020-04-08
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 2 Completed
NCT00524277 2020-03-30
Vaccine Therapy in Treating Patients With Breast Cancer
San Antonio Military Medical Center
Phase 2 Completed
NCT01363206 2020-03-19
GIPI
Northern California Melanoma Center
Phase 2 Completed
NCT00514215 2020-03-05
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00343109 2020-02-12
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
University of Washington
Phase 2 Completed
NCT00001564 2019-11-29
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00488982 2019-11-20
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
University of California, San Francisco
Phase 2 Completed
NCT01334515 2019-10-21
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00254592 2019-02-28
Neoadjuvant Treatment of Breast Cancer
University of California, Irvine
Phase 2 Completed
NCT00450463 2018-11-29
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00363649 2018-11-13
Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00257322 2018-10-31
Cellular Immune Augmentation in Colon and Rectal Cancer
University of California, Irvine
Phase 2 Completed
NCT00940342 2018-09-19
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00400517 2018-08-28
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00256243 2018-03-02
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
University of California, Irvine
Phase 2 Completed
NCT00458601 2018-01-16
ACT III
Celldex Therapeutics
Phase 2 Completed
NCT00411086 2017-12-05
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00466960 2017-08-28
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
University of Washington
Phase 2 Completed
NCT00678054 2017-08-23
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
University of California, San Francisco
Phase 2 Completed
NCT00462605 2017-07-18
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003199 2017-07-12
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT01158118 2017-06-05
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Phase 2 Completed
NCT00157573 2017-05-08
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00040937 2016-12-08
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
SWOG Cancer Research Network
Phase 2 Completed
NCT00548847 2016-10-26
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation
Emory University
Phase 2 Completed
NCT00533923 2016-07-18
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00948480 2016-07-15
DCVaccineMel
Hoag Memorial Hospital Presbyterian
Phase 2 Completed